Form 4: Vanda Pharmaceuticals CFO Kevin Patrick Moran Increases Stake in Company
SEC Form 4 Filing
Kevin Patrick Moran, SVP, CFO & Treasurer of Vanda Pharmaceuticals, recently purchased 2,000 shares of common stock at a price of $4.3894 per share.
Summary
- On February 21, 2025, Kevin Patrick Moran, the SVP, CFO & Treasurer of Vanda Pharmaceuticals, acquired 2,000 shares of the company's common stock.
- The purchase price was $4.3894 per share.
- Following the transaction, Mr. Moran directly owns 355,763 shares of Vanda Pharmaceuticals.
- He also indirectly owns 635 shares through his wife.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The CFO's purchase of shares suggests confidence in the company, but it's a relatively small transaction.
Positives
- The CFO's purchase of company stock may signal confidence in the company's future prospects.
Industry Context
Insider buying is often seen as a positive sign, suggesting that a company's management believes the stock is undervalued.
Stakeholder Impact
- The stock purchase could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/21/2025 | Date of the transaction: Kevin Patrick Moran purchased 2,000 shares of Vanda Pharmaceuticals. |
| 02/24/2025 | Date of signature on the Form 4 filing. |
Keywords
Vanda Pharmaceuticals, Kevin Patrick Moran, insider trading, Form 4, stock purchase, VNDA, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.